185 related articles for article (PubMed ID: 20213666)
1. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
Moreno A; Pérez-Elías MJ; Casado JL; Fortún J; Bárcena R; Quereda C; Del Campo S; Gutiérrez C; Pastor O; Nuño J; Fernandez A; Moreno S
Liver Transpl; 2010 Apr; 16(4):530-2. PubMed ID: 20213666
[No Abstract] [Full Text] [Related]
2. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review.
Miro JM; Ricart MJ; Trullas JC; Cofan F; Cervera C; Brunet M; Tuset M; Manzardo C; Oppenheimer F; Moreno A
Transplant Proc; 2010 Nov; 42(9):3887-91. PubMed ID: 21094878
[TBL] [Abstract][Full Text] [Related]
3. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy.
Soriano-Sarabia N; Abad MA; Vallejo A; Gutiérrez S; Leal M
Clin Microbiol Infect; 2006 Mar; 12(3):290-3. PubMed ID: 16451419
[TBL] [Abstract][Full Text] [Related]
4. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation.
Ciuffreda D; Pantaleo G; Pascual M
Transpl Int; 2007 Aug; 20(8):649-58. PubMed ID: 17425723
[TBL] [Abstract][Full Text] [Related]
5. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
Fraaij PL; Verweel G; van Rossum AM; van Lochem EG; Schutten M; Weemaes CM; Hartwig NG; Burger DM; de Groot R
Clin Infect Dis; 2005 Feb; 40(4):604-8. PubMed ID: 15712085
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children.
Resino S; Resino R; Maria Bellón J; Micheloud D; Gutiérrez MD; de José MI; Ramos JT; Fontelos PM; Ciria L; Muñoz-Fernández MA;
Clin Infect Dis; 2006 Jul; 43(2):243-52. PubMed ID: 16779753
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir: is a 400 mg once-daily dose enough?
Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
[No Abstract] [Full Text] [Related]
9. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A; Flanigan TP; Carter EJ
Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients.
Marfo K; Greenstein S
Transplant Proc; 2009 Nov; 41(9):3796-9. PubMed ID: 19917390
[TBL] [Abstract][Full Text] [Related]
11. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
12. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy.
Posavad CM; Wald A; Kuntz S; Huang ML; Selke S; Krantz E; Corey L
J Infect Dis; 2004 Aug; 190(4):693-6. PubMed ID: 15272395
[TBL] [Abstract][Full Text] [Related]
13. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract.
Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L
AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873
[No Abstract] [Full Text] [Related]
14. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
Papendorp SG; van den Berk GE
AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
[No Abstract] [Full Text] [Related]
15. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
16. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
17. Laser scanning confocal ophthalmoscopy and polarimetry of human immunodeficiency virus patients without retinopathy, under antiretroviral therapy.
Besada E; Shechtman D; Black G; Hardigan PC
Optom Vis Sci; 2007 Mar; 84(3):189-96. PubMed ID: 17435532
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
19. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions.
Soriano V; Rivas P; Nuñez M
Clin Infect Dis; 2008 Dec; 47(11):1486-9. PubMed ID: 18937578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
